New therapeutic approach shows promise for pediatric high-grade gliomas
Paediatric high-grade gliomas (pHGG) in particular are a mostly fatal disease group with a median survival time of less than 18 months after diagnosis and limited treatment options. A research team from MedUni Vienna/University Hospital Vienna, the Dana-Farber Cancer Institute and the University of Michigan Medical School identified Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) as a promising therapeutic approach.
Yorumlar